Newman Dignan & Sheerar Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 3.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 31,125 shares of the biopharmaceutical company’s stock after acquiring an additional 1,050 shares during the period. Newman Dignan & Sheerar Inc.’s holdings in Pfizer were worth $1,220,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. 1 North Wealth Services LLC purchased a new position in Pfizer during the 3rd quarter worth approximately $29,000. Bourgeon Capital Management LLC acquired a new position in Pfizer during the third quarter worth approximately $32,000. Salomon & Ludwin LLC increased its position in Pfizer by 362.7% during the third quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 700 shares during the period. B & T Capital Management DBA Alpha Capital Management purchased a new stake in Pfizer in the third quarter valued at approximately $36,000. Finally, Sageworth Trust Co purchased a new stake in Pfizer in the third quarter valued at approximately $44,000. 70.21% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer stock opened at $40.67 on Thursday. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The stock has a 50 day moving average of $38.90 and a two-hundred day moving average of $38.18. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $221.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 4.24 and a beta of 0.65.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, January 30th. This is an increase from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 annualized dividend and a dividend yield of 3.74%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
Several equities research analysts have recently weighed in on PFE shares. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Tuesday, October 1st. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America initiated coverage on shares of Pfizer in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Finally, Royal Bank of Canada began coverage on shares of Pfizer in a research note on Monday, January 6th. They set an “outperform” rating and a $46.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.41.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Bid-Ask Spread
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.